Bausch Health Companies Inc. (TSX: BHC)
Canada
· Delayed Price · Currency is CAD | Market Cap | 3.54B |
| Revenue (ttm) | 12.20B |
| Net Income (ttm) | -618.93M |
| Shares Out | 366.80M |
| EPS (ttm) | -1.69 |
| PE Ratio | n/a |
| Forward PE | 2.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 110,115 |
| Open | 9.76 |
| Previous Close | 9.74 |
| Day's Range | 9.60 - 9.81 |
| 52-Week Range | 8.10 - 15.43 |
| Beta | 0.90 |
| Analysts | n/a |
| Price Target | 13.34 (+38.31%) |
| Earnings Date | Aug 1, 2024 |
About Bausch Health Companies
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in... [Read more]
Financial Performance
In 2023, BHC's revenue was $8.76 billion, an increase of 7.79% compared to the previous year's $8.12 billion. Losses were -$592.00 million, 179.2% more than in 2022.
Financial numbers in USD Financial StatementsNews
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2024 annual meeting of shareholders. Annual Meeting Results The 10 directors...
Bausch issues update on Xifaxan patent dispute with Norwich
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
LAVAL, QC / ACCESSWIRE / May 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business Salix Pharmaceuticals, today announced certain updates related to its litigat...
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adults Overt Hepatic Encephalopathy is caused by cirrhosis of the liver As complications from chron...
Why Bausch Health Stock Plunged After Posting First Quarter 2024 Results
Why Bausch Health Companies Stock Dived by More Than 7% Today
A large red number on the bottom line attracted the wrong kind of investor attention for the company.
Bausch Health investors are left in a holding pattern as 2 major overhangs remain unresolved
We're maintaining our 4 rating as we consider our next steps.
Why Bausch Health Companies Shares Are Falling After Q1 Results
Bausch Health Companies Inc. (NYSE: BHC) shares are trading lower on Thursday after reporting first-quarter results. The company reported adjusted quarterly earnings per share of 59 cents, missing th...
Bausch Health Companies (BHC) Q1 2024 Earnings Call Transcript
Bausch Health Companies Inc. 2024 Q1 - Results - Earnings Call Presentation
Bausch Health Companies GAAP EPS of -$0.17, revenue of $2.15B
Bausch Health Companies press release (BHC): Q1 GAAP EPS of -$0.17. Revenue of $2.15B (+11% Y/Y) •Year-over-year revenue growth in all segments on both a Report
Bausch Health Announces First Quarter 2024 Results
First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basis Year-over-year revenue growth in all segments on both a Reported and Organic1 Basis GAAP Net Loss Attributable...
Bausch Health to Announce First-Quarter 2024 Results on May 2
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a confere...
Bausch wins US appeal to block Alvogen generic of diarrhea drug
A U.S. appeals court on Thursday affirmed a decision for Bausch Health that barred rival drugmaker Alvogen from marketing a proposed generic version of Bausch's diarrhea treatment Xifaxan until 2029.
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for ...
Bausch Health pares gain after appeals court affirms ruling in Norwich patent case
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgari...
Bausch Health drops after suing Amneal Pharma over Xifaxan generic
Bausch Health sues Amneal Pharma over Xifaxan generic
Bausch Health (BHC) files a patent lawsuit against Amneal Pharmaceuticals (AMRX) over a generic version of its bowel therapy Xifaxan. Read more here.
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
LAVAL, QC / ACCESSWIRE / April 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) along with its gastroenterology business, Salix Pharmaceuticals, Inc., announced that it filed a lawsuit today...
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
LAVAL, QC / ACCESSWIRE / April 3, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the first public drug plan listings for PrUCERIS® (budeso...
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
Salix Pharmaceuticals Releases Fourth Annual Patient Perspectives IBS Impact Report LAVAL, QC / ACCESSWIRE / April 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (...
Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced fifteen podium...
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced that it is supporting a Phase 2 inve...
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
Salix Pharmaceuticals Releases Findings from First Colonoscopy Awareness Survey LAVAL, QC / ACCESSWIRE / March 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology busin...